GlassScriptPhysician profile
Robert A Strzinek
NPI 1568480457
$2,836.16
in general payments reported to CMS, 2019-2025
23 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $195 · 2021: $90.57 · 2022: $38.59 · 2023: $274 · 2024: $93.42 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,362.55 | 2019 | |
| Novo Nordisk INC | $788.61 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $130.03 | 2020-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $122.96 | 2020-2025 | |
| Abbott Laboratories | $115.61 | 2019-2023 | Assurity, Octrode |
| Exact Sciences Corporation | $95.32 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $67.18 | 2020-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $37.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $24.41 | 2025 | Breztri |
| Biogen, INC. | $22.91 | 2020 | |
| Eisai INC. | $19.27 | 2021 | |
| Ascensia Diabetes Care US INC. | $17.90 | 2024 | |
| Halozyme INC | $16.16 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.42 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strzinek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.